Literature DB >> 17287966

[Cardiac disease in patients with tumors and tumor therapy].

U C Hoppe1.   

Abstract

Cardiac disease may occur as a direct complication of heart tumors or as an indirect complication of malignancies due to antineoplastic therapy. While primary cardiac neoplasias are rare, metastases to various cardiac structures are common. The cardiotoxicity of anticancer agents can lead to significant complications that may affect patients being treated for various non-cardiac neoplasias. The severity of such cardiovascular damage depends on many factors, such as the site of molecular action, the immediate and cumulative dose, the method of administration, and the presence of any underlying cardiac condition. Moreover, toxicity can be affected by concomitant radiation. Cardiotoxic effects can occur during the administration of the drug, but they may not manifest themselves until months or years after the patient has been treated. Since cardiovascular disease and cancer are both common, precise knowledge of therapeutic interactions and complications is necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287966     DOI: 10.1007/s00108-006-1779-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

Review 1.  Cardiovascular magnetic resonance of primary tumors of the heart: A review.

Authors:  David S Fieno; Rola Saouaf; Louise E J Thomson; Aiden Abidov; John D Friedman; Daniel S Berman
Journal:  J Cardiovasc Magn Reson       Date:  2006       Impact factor: 5.364

Review 2.  Cardiac toxicity following thoracic radiation.

Authors:  Robert G Prosnitz; Yu Husuan Chen; Lawrence B Marks
Journal:  Semin Oncol       Date:  2005-04       Impact factor: 4.929

3.  A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.

Authors:  M S Ewer; M K Ali; B Mackay; S Wallace; M Valdivieso; S S Legha; R S Benjamin; T P Haynie
Journal:  J Clin Oncol       Date:  1984-02       Impact factor: 44.544

Review 4.  Pathogenesis of cardiotoxicity induced by anthracyclines.

Authors:  Perry Elliott
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

5.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

6.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Nader Rifai; Virginia M Dalton; Donna E Levy; Lewis B Silverman; Stuart R Lipsitz; Steven D Colan; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall A Schorin; Richard D Gelber; Stephen E Sallan
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

9.  High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.

Authors:  Z M Quezado; W H Wilson; R E Cunnion; M M Parker; D Reda; G Bryant; F P Ognibene
Journal:  Ann Intern Med       Date:  1993-01-01       Impact factor: 25.391

10.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Authors:  E L Trimble; J D Adams; D Vena; M J Hawkins; M A Friedman; J S Fisherman; M C Christian; R Canetta; N Onetto; R Hayn
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.